Shiraj Sen
Research Subjects
Shiraj Sen has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Aung Naing
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
18 shared publications - David S. Hong
Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
18 shared publications - Funda Meric-Bernstam
Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, USA
18 shared publications - Robert S. Benjamin
Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 450, Houston, TX 77030, USA
18 shared publications - Roberto Carmagnani Pestana
Hospital Israelita Albert Einstein, São Paulo, Brazil
18 shared publications - Shreyaskumar R. Patel
Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
18 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)
Treemap of most common drug mechanisms for patients treated in biomarker-matched studies.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)
Treemap of most common drug mechanisms for patients treated in biomarker-matched studies.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)
Summary of response outcomes across subgroups
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)
Summary of response outcomes across subgroups
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Table S3: Study Representativeness Table
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Table S3: Study Representativeness Table
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Figure S1: Evaluation of azenosertib in cellular assays.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Figure S1: Evaluation of azenosertib in cellular assays.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Table S5A Distribution of cells according to cell cycle state; Supplementary Table S5B: Distribution of cells according to mitotic and cell cycle phase
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Table S5A Distribution of cells according to cell cycle state; Supplementary Table S5B: Distribution of cells according to mitotic and cell cycle phase
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Table S1: Treatment and response characteristics of selected CDX models tested with at least 60mg/kg azenosertib as single agent
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Table S1: Treatment and response characteristics of selected CDX models tested with at least 60mg/kg azenosertib as single agent
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Figure S5. Additional optimization of azenosertib intermittent dosing schedule
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Figure S5. Additional optimization of azenosertib intermittent dosing schedule
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Figure S3. Azenosertib efficacy in solid tumor xenograft models.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Figure S3. Azenosertib efficacy in solid tumor xenograft models.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Table S6: Distribution of cells according to γH2Ax status in both treatments conditions (A) or in azenosertib treated cells in different cell cycle phase (B) or mitotic (C) context for each cell lines.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Table S6: Distribution of cells according to γH2Ax status in both treatments conditions (A) or in azenosertib treated cells in different cell cycle phase (B) or mitotic (C) context for each cell lines.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Table S4: ADME, physicochemical, and pharmacokinetic properties of azenosertib.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors
Supplementary Table S4: ADME, physicochemical, and pharmacokinetic properties of azenosertib.